{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:25:19Z","timestamp":1792887919216,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T00:00:00Z","timestamp":1522022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40257-018-0348-7","type":"journal-article","created":{"date-parts":[[2018,3,26]],"date-time":"2018-03-26T06:26:06Z","timestamp":1522045566000},"page":"543-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review"],"prefix":"10.1007","volume":"19","author":[{"given":"Nathan","family":"Jetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Chandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,26]]},"reference":[{"key":"348_CR1","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/bjd.14852","volume":"177","author":"JA Siegel","year":"2017","unstructured":"Siegel JA, Korgavkar K, Weinstock MA. Current perspective on actinic keratosis: a review. Br J Dermatol. 2017;177:350\u20138.","journal-title":"Br J Dermatol"},{"key":"348_CR2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5694\/j.1326-5377.1989.tb136588.x","volume":"150","author":"R Marks","year":"1989","unstructured":"Marks R, Jolley D, Dorevitch AP, Selwood TS. The incidence of non-melanocytic skin cancers in an Australian population: results of a five-year prospective study. Med J Aust. 1989;150:475\u20138.","journal-title":"Med J Aust"},{"issue":"21","key":"348_CR3","first-page":"439","volume":"2007","author":"P Calzavara-Pinton","year":"2006","unstructured":"Calzavara-Pinton P, Venturini M, Sala R. Photodynamic therapy: update 2006. Part 2: Clinical results. J Eur Acad Dermatol Venereol. 2006;2007(21):439\u201351.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"348_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s13555-014-0049-y","volume":"4","author":"A Dodds","year":"2014","unstructured":"Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther (Heidelb). 2014;4:11\u201331.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"348_CR5","first-page":"2628","volume":"38","author":"TJ Dougherty","year":"1978","unstructured":"Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res. 1978;38(8):2628\u201335.","journal-title":"Cancer Res"},{"issue":"4","key":"348_CR6","doi-asserted-by":"publisher","first-page":"27592","DOI":"10.1016\/1011-1344(92)85108-7","volume":"14","author":"JC Kennedy","year":"1992","unstructured":"Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992;14(4):27592.","journal-title":"J Photochem Photobiol B"},{"key":"348_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s101030200027","volume":"17","author":"L Brancaleon","year":"2002","unstructured":"Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci. 2002;17:173\u201386.","journal-title":"Lasers Med Sci"},{"key":"348_CR8","first-page":"340","volume":"16","author":"P Babilas","year":"2006","unstructured":"Babilas P, Landthaler M, Szeimies R. Photodynamic therapy in dermatology. Eur J Dermatol. 2006;16:340.","journal-title":"Eur J Dermatol"},{"key":"348_CR9","first-page":"115","volume-title":"Photodynamic therapy at the cellular level: the principles of 5-aminolevulinic acid photodynamic therapy","author":"A Juzeniene","year":"2007","unstructured":"Juzeniene A. Photodynamic therapy at the cellular level: the principles of 5-aminolevulinic acid photodynamic therapy. Trivandrum: Research Signpost; 2007. p. 115\u201340."},{"key":"348_CR10","doi-asserted-by":"publisher","first-page":"s23","DOI":"10.1080\/095466302317414663","volume":"13","author":"E Jeffes","year":"2002","unstructured":"Jeffes E. Levulan: the first approved topical photosensitizer for the treatment of actinic keratosis. J Dermatol Treat. 2002;13:s23.","journal-title":"J Dermatol Treat"},{"key":"348_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1039\/b201027p","volume":"1","author":"CJ Kelty","year":"2002","unstructured":"Kelty CJ, Brown NJ, Reed MWR, Ackroyd R. The use of 5-aminolaevulinic acid as a photosensitiser in photodynamic therapy and photodiagnosis. Photochem Photobiol Sci. 2002;1:158\u201368.","journal-title":"Photochem Photobiol Sci"},{"key":"348_CR12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/bjd.14498","volume":"175","author":"U Reinhold","year":"2016","unstructured":"Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz\u00ae) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED\u00ae lamp. Br J Dermatol. 2016;175:696\u2013705.","journal-title":"Br J Dermatol"},{"key":"348_CR13","unstructured":"Center for Drug Evaluation and Research. Approval package for application number: 208081Orig1s000. 5 October 2016."},{"key":"348_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1067\/mjd.2001.114288","volume":"45","author":"EW Jeffes","year":"2001","unstructured":"Jeffes EW, McCullough JL, Weinstein GD, Kaplan R, Glazer SD, Taylor JR. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 2001;45:96\u2013104.","journal-title":"J Am Acad Dermatol"},{"key":"348_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archderm.140.1.41","volume":"140","author":"DF Piacquadio","year":"2004","unstructured":"Piacquadio DF, Chen DM, Farber HF, Fowler JF, Glazer SD, Goodman JJ, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol. 2004;140:41.","journal-title":"Arch Dermatol"},{"key":"348_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1365-2133.2010.09873.x","volume":"163","author":"RM Szeimies","year":"2010","unstructured":"Szeimies RM, Radny P, Sebastian M, Borrosch F, Dirschka T, Krahn-Senftleben G, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol. 2010;163:386\u201394.","journal-title":"Br J Dermatol"},{"key":"348_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2133.2011.10613.x","volume":"166","author":"T Dirschka","year":"2012","unstructured":"Dirschka T, Radny P, Dominicus R, Mensing H, Br\u00fcning H, Jenne L, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol. 2012;166:137\u201346.","journal-title":"Br J Dermatol"},{"key":"348_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pdpdt.2016.04.017","volume":"17","author":"W Jerjes","year":"2017","unstructured":"Jerjes W, Hamdoon Z, Abdulkareem AA, Hopper C. Photodynamic therapy in the management of actinic keratosis: Retrospective evaluation of outcome. Photodiagn Photodyn Ther. 2017;17:200\u20134.","journal-title":"Photodiagn Photodyn Ther"},{"key":"348_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/j.1365-2133.2009.09492.x","volume":"162","author":"Z Apalla","year":"2010","unstructured":"Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol. 2010;162:171\u20135.","journal-title":"Br J Dermatol"},{"key":"348_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/TP.0b013e318180731e","volume":"86","author":"A Wennberg","year":"2008","unstructured":"Wennberg A, Stenquist B, Stockfleth E, Keohane S, Lear JT, Jemec G, et al. Photodynamic therapy with methyl aminolevulinate for prevention of new skin lesions in transplant recipients: a randomized study. Transplantation. 2008;86:423\u20139.","journal-title":"Transplantation"},{"key":"348_CR21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/00015550510042868","volume":"86","author":"HC Wulf","year":"2006","unstructured":"Wulf HC, Pavel S, Stender I, Ahb Bakker-Wensveen C. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol. 2006;86:25\u20138.","journal-title":"Acta Derm Venereol"},{"key":"348_CR22","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1067\/mjd.2002.119649","volume":"47","author":"RM Szeimies","year":"2002","unstructured":"Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinton P, Zane C, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol. 2002;47:258\u201362.","journal-title":"J Am Acad Dermatol"},{"key":"348_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/lsm.20470","volume":"39","author":"C Zane","year":"2007","unstructured":"Zane C, Capezzera R, Sala R, Venturini M, Calzavara-Pinton P. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med. 2007;39:203\u20139.","journal-title":"Lasers Surg Med"},{"key":"348_CR24","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/jdv.13076","volume":"29","author":"MC Fargnoli","year":"2015","unstructured":"Fargnoli MC, Piccioni A, Neri L, Tambone S, Pellegrini C, Peris K. Conventional vs. daylight methyl aminolevulinate photodynamic therapy for actinic keratosis of the face and scalp: an intra-patient, prospective, comparison\u00a0study in Italy. J Eur Acad Dermatol Venereol. 2015;29:1926\u201332.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"348_CR25","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/bjd.13138","volume":"171","author":"DM Rubel","year":"2014","unstructured":"Rubel DM, Spelman L, Murrell DF, See JA, Hewitt D, Foley P, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. Br J Dermatol. 2014;171:1164\u201371.","journal-title":"Br J Dermatol"},{"key":"348_CR26","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/jdv.13228","volume":"29","author":"J Lacour","year":"2015","unstructured":"Lacour J, Ulrich C, Gilaberte Y, Von Felbert V, Basset-Seguin N, Dreno B, et al. Daylight photodynamic therapy with methyl aminolevulinate cream is effective and nearly painless in treating actinic keratoses: a randomised, investigator-blinded, controlled, phase III study throughout Europe. J Eur Acad Dermatol Venereol. 2015;29:2342\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"348_CR27","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/jdv.14177","volume":"31","author":"E Sotiriou","year":"2017","unstructured":"Sotiriou E, Apalla Z, Vrani F, Lazaridou E, Vakirlis E, Lallas A, et al. Daylight photodynamic therapy vs. Conventional photodynamic therapy as skin cancer preventive treatment in patients with face and scalp cancerization: an intra-individual comparison study. J Eur Acad Dermatol Venereol. 2017;31:1303\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"348_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1440-0960.2011.00785.x","volume":"52","author":"DT Tran","year":"2011","unstructured":"Tran DT, Salmon R. Field treatment of facial and scalp actinic keratoses with photodynamic therapy: survey of patient perceptions of treatment satisfaction and outcomes. Australas J Dermatol. 2011;52:195\u2013201.","journal-title":"Australas J Dermatol"},{"key":"348_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/14764170802056117","volume":"10","author":"EP Tierney","year":"2008","unstructured":"Tierney EP, Eide MJ, Jacobsen G, Ozog D. Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes. J Cos Laser Therapy. 2008;10:81\u20136.","journal-title":"J Cos Laser Therapy"},{"key":"348_CR30","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/lsm.22682","volume":"49","author":"MJ Vanaman Wilson","year":"2017","unstructured":"Vanaman Wilson MJ, Jones IT, Wu DC, Goldman MP. A randomized, double-blind, placebo-controlled clinical trial evaluating the role of systemic antihistamine therapy for the reduction of adverse effects associated with topical 5-aminolevulinic acid photodynamic therapy. Lasers Surg Med. 2017;49:738\u201342.","journal-title":"Lasers Surg Med"},{"key":"348_CR31","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/1346-8138.12310","volume":"40","author":"N Tanaka","year":"2013","unstructured":"Tanaka N, Ohata C, Ishii N, Imamura K, Ueda A, Furumura M, et al. Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients. J Dermatol. 2013;40:962\u20137.","journal-title":"J Dermatol"},{"key":"348_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.pdpdt.2017.07.010","volume":"20","author":"S Yazdanyar","year":"2017","unstructured":"Yazdanyar S, Zarchi K, Jemec GBE. Pain during topical photodynamic therapy\u2014comparing methyl aminolevulinate (Metvix\u00ae) to aminolaevulinic acid (Ameluz\u00ae); an intra-individual clinical study. Photodiagnosis Photodyn Ther. 2017;20:6\u20139.","journal-title":"Photodiagnosis Photodyn Ther."},{"issue":"4","key":"348_CR33","first-page":"353","volume":"5","author":"A Kasche","year":"2006","unstructured":"Kasche A, Luderchmidt S, Ring J, Hein R. Photodynamic therapy induces less pain in patients treated with methyl aminolevulinate compared to aminolevulinic acid. J Drugs Dermatol. 2006;5(4):353\u20136.","journal-title":"J Drugs Dermatol"},{"key":"348_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1365-2133.2007.07946.x","volume":"157","author":"FJ Moloney","year":"2007","unstructured":"Moloney FJ, Collins P. Randomized, double-blind, prospective study to compare topical 5-aminolaevulinic acid methylester with topical 5-aminolaevulinic acid photodynamic therapy for extensive scalp actinic keratosis. Br J Dermatol. 2007;157:87\u201391.","journal-title":"Br J Dermatol"},{"key":"348_CR35","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1039\/b823378k","volume":"8","author":"JM Steinbauer","year":"2009","unstructured":"Steinbauer JM, Schreml S, Babilas P, Zeman F, Karrer S, Landthaler M, et al. Topical photodynamic therapy with porphyrin precursors-assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci. 2009;8:1111\u20136.","journal-title":"Photochem Photobiol Sci"},{"key":"348_CR36","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/j.1468-3083.2010.03670.x","volume":"24","author":"A Arits","year":"2010","unstructured":"Arits A, Weert VD, Nelemans PJ, Kelleners-Smeets N. Pain during topical photodynamic therapy: uncomfortable and unpredictable. J Eur Acad Dermatol Venereol. 2010;24:1452\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"348_CR37","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2340\/00015555-1223","volume":"92","author":"M Ga\u00e1l","year":"2012","unstructured":"Ga\u00e1l M, Otrosinka S, Balt\u00e1s E, Ocsai H, Ol\u00e1h J, Kem\u00e9ny L, et al. Photodynamic therapy of non-melanoma skin cancer with methyl aminolaevulinate is associated with less pain than with aminolaevulinic acid. Acta Derm Venereol. 2012;92:173\u20135.","journal-title":"Acta Derm Venereol"},{"key":"348_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1600-0781.2012.00684.x","volume":"28","author":"SH Ibbotson","year":"2012","unstructured":"Ibbotson SH, Valentine R, Hearn R. Is the pain of topical photodynamic therapy with methyl aminolevulinate any different from that with 5-aminolaevulinic acid? Photodermatol Photoimmunol Photomed. 2012;28:272\u20133.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"348_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000349992","volume":"226","author":"P Gholam","year":"2013","unstructured":"Gholam P, Kroehl V, Enk AH. Dermatology life quality index and side effects after topical photodynamic therapy of actinic keratosis. Dermatology. 2013;226:253\u20139.","journal-title":"Dermatology"},{"key":"348_CR40","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/bjd.13326","volume":"171","author":"N Neittaanm\u00e4ki-Perttu","year":"2014","unstructured":"Neittaanm\u00e4ki-Perttu N, Karppinen TT, Gr\u00f6nroos M, Tani TT, Snellman E. Daylight photodynamic therapy for actinic keratoses: a randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate. Br J Dermatol. 2014;171:1172\u201380.","journal-title":"Br J Dermatol"},{"key":"348_CR41","first-page":"19","volume":"9","author":"GM Martin","year":"2016","unstructured":"Martin GM. In-office painless aminolevulinic acid photodynamic therapy: a proof of concept study and clinical experience in more than 100 patients. J Clin Aesthetic Dermatol. 2016;9:19.","journal-title":"J Clin Aesthetic Dermatol"},{"key":"348_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1034\/j.1600-0781.2003.00024.x","volume":"19","author":"C Clark","year":"2003","unstructured":"Clark C, Bryden A, Dawe R, Moseley H, Ferguson J, Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources. Photodermatol Photoimmunol Photomed. 2003;19:134\u201341.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"348_CR43","doi-asserted-by":"publisher","first-page":"652","DOI":"10.2340\/00015555-1425","volume":"92","author":"LR Braathen","year":"2012","unstructured":"Braathen LR. Daylight photodynamic therapy in private practice in Switzerland: gain without pain. Acta Derm Venereol. 2012;92:652.","journal-title":"Acta Derm Venereol"},{"key":"348_CR44","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/j.1365-2133.2008.08450.x","volume":"158","author":"SR Wiegell","year":"2008","unstructured":"Wiegell SR, Haedersdal M, Philipsen PA, Eriksen P, Enk CD, Wulf HC. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol. 2008;158:740\u20136.","journal-title":"Br J Dermatol"},{"key":"348_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2340\/00015555-2205","volume":"96","author":"N Neittaanm\u00e4ki-Perttu","year":"2016","unstructured":"Neittaanm\u00e4ki-Perttu N, Gr\u00f6nroos M, Karppinen T, Snellman E, Rissanen P. Photodynamic therapy for actinic keratoses: a randomized prospective non-sponsored cost-effectiveness study of daylight-mediated treatment compared with light-emitting diode treatment. Acta Derm Venereol. 2016;96:241.","journal-title":"Acta Derm Venereol"},{"key":"348_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1600-0781.2012.00681.x","volume":"28","author":"SH Ibbotson","year":"2012","unstructured":"Ibbotson SH, Ferguson J. Ambulatory photodynamic therapy using low irradiance inorganic light-emitting diodes for the treatment of non-melanoma skin cancer: an open study. Photodermatol Photoimmunol Photomed. 2012;28:235\u20139.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"348_CR47","doi-asserted-by":"crossref","unstructured":"Ang JM, Riaz IB, Kamal MU, Parah G, Zeitouni NC. Photodynamic therapy and pain: a systematic review. Photodiagn Photodyn Ther. 2017;19:308\u201344.","DOI":"10.1016\/j.pdpdt.2017.07.002"},{"key":"348_CR48","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1365-2230.2008.02755.x","volume":"33","author":"J Paoli","year":"2008","unstructured":"Paoli J, Halldin C, Ericson MB, Wennberg A. Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses. Clin Exp Dermatol. 2008;33:559\u201364.","journal-title":"Clin Exp Dermatol"},{"key":"348_CR49","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1365-2133.2008.09024.x","volume":"160","author":"CB Halldin","year":"2009","unstructured":"Halldin CB, Paoli J, Sandberg C, Gonzalez H, Wennberg AM. Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Br J Dermatol. 2009;160:795\u2013800.","journal-title":"Br J Dermatol"},{"key":"348_CR50","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2133.2009.09184.x","volume":"161","author":"C Serra-Guillen","year":"2009","unstructured":"Serra-Guillen C, Hueso L, Nagore E, Vila M, Llombart B, Requena Caballero C, et al. Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratoses of the frontotemporal zone. Br J Dermatol. 2009;161:353\u20136.","journal-title":"Br J Dermatol"},{"key":"348_CR51","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/bjd.13547","volume":"173","author":"A Klein","year":"2015","unstructured":"Klein A, Karrer S, Horner C, Werner A, Heinlin J, Zeman F, et al. Comparing cold-air analgesia, systemically administered analgesia and scalp nerve blocks for pain management during photodynamic therapy for actinic keratosis of the scalp presenting as field cancerization: a randomized controlled trial. Br J Dermatol. 2015;173:192\u2013200.","journal-title":"Br J Dermatol"},{"key":"348_CR52","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamadermatol.2016.0502","volume":"152","author":"JS Kirby","year":"2016","unstructured":"Kirby JS, Delikat A, Leslie D, Miller JJ. Bundled payment models for actinic keratosis management. JAMA Dermatol. 2016;152:789\u201397.","journal-title":"JAMA Dermatol"},{"key":"348_CR53","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2165\/11538670-000000000-00000","volume":"28","author":"E Wilson","year":"2010","unstructured":"Wilson E. Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (Solar) Keratoses a decision tree model. Pharmacoeconomics. 2010;28:1055\u201364.","journal-title":"Pharmacoeconomics"},{"key":"348_CR54","first-page":"573","volume":"145","author":"GL Colombo","year":"2010","unstructured":"Colombo GL, Chimenti S, Di Matteo S, Fargnoli MC, Frascione P, Silipo V, et al. Cost-effectiveness analysis of topical treatments for actinic keratosis in the perspective of the Italian health care system. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societ\u00c3 italiana di dermatologia e sifilografia. 2010;145:573.","journal-title":"Giornale italiano di dermatologia e venereologia : organo ufficiale, Societ\u00c3 italiana di dermatologia e sifilografia"},{"key":"348_CR55","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/bjd.12844","volume":"170","author":"C Zane","year":"2014","unstructured":"Zane C, Facchinetti E, Rossi MT, Specchia C, Calzavara-Pinton PG. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol. 2014;170:1143\u201350.","journal-title":"Br J Dermatol"},{"key":"348_CR56","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12325-015-0211-7","volume":"32","author":"E Soini","year":"2015","unstructured":"Soini E, Hallinen T, Sokka A, Saarinen K. Cost-utility of first-line actinic keratosis treatments in Finland. Adv Ther. 2015;32:455\u201376.","journal-title":"Adv Ther"},{"key":"348_CR57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40273-016-0462-4","volume":"35","author":"S Vale","year":"2017","unstructured":"Vale S, Hill D, Feldman S. Pharmacoeconomic considerations in treating actinic keratosis: an update. Pharmacoeconomics. 2017;35:177\u201390.","journal-title":"Pharmacoeconomics"},{"key":"348_CR58","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2133.2006.07692.x","volume":"156","author":"D Berker de","year":"2007","unstructured":"de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222\u201330.","journal-title":"Br J Dermatol"},{"key":"348_CR59","first-page":"430","volume":"13","author":"R Szeimies","year":"2015","unstructured":"Szeimies R, Dirschka T, Prechtl A, Melzer A. Efficacy of low-dose 5-fluorouracil\/salicylic acid in actinic keratoses in relation to treatment duration. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 2015;13:430\u20138.","journal-title":"JDDG Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"348_CR60","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13555-016-0161-2","volume":"7","author":"E Stockfleth","year":"2011","unstructured":"Stockfleth E, von Kiedrowski R, Dominicus R, Ryan J, Ellery A, Falques M, et al. Efficacy and safety of 5-fluorouracil 0.5%\/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial. Dermatol Ther (Heidelb). 2011;7:81\u201396.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"348_CR61","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1365-2133.2011.10387.x","volume":"165","author":"E Stockfleth","year":"2011","unstructured":"Stockfleth E, Kerl H, Zwingers T, Willers C. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br J Dermatol. 2011;165:1101\u20138.","journal-title":"Br J Dermatol"},{"key":"348_CR62","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1684\/ejd.2012.1707","volume":"22","author":"E Stockfleth","year":"2012","unstructured":"Stockfleth E, Zwingers T, Willers C. Recurrence rates and patient assessed outcomes of 0.5% 5-fluorouracil in combination with salicylic acid treating actinic keratoses. Eur J Dermatol. 2012;22:370\u20134.","journal-title":"Eur J Dermatol"},{"key":"348_CR63","first-page":"167","volume":"5","author":"B Berman","year":"2006","unstructured":"Berman B, Villa AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol. 2006;5:167\u201373.","journal-title":"J Drugs Dermatol"},{"key":"348_CR64","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1684\/ejd.2010.1010","volume":"20","author":"C Ulrich","year":"2010","unstructured":"Ulrich C, Johannsen A, R\u00f6wert-Huber J, Ulrich M, Sterry W, Stockfleth E. Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses. Eur J Dermatol. 2010;20:482\u20138.","journal-title":"Eur J Dermatol"},{"key":"348_CR65","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4103\/0378-6323.27749","volume":"72","author":"F Iraji","year":"2006","unstructured":"Iraji F, Asilian A, Amir HS, Safavai A. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venereol Leprol. 2006;72:346\u20139.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"348_CR66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","volume":"40","author":"JE Wolf","year":"2001","unstructured":"Wolf JE, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709\u201313.","journal-title":"Int J Dermatol"},{"key":"348_CR67","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/archderm.1997.03890460061007","volume":"133","author":"JK Rivers","year":"1997","unstructured":"Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol. 1997;133:1239\u201342.","journal-title":"Arch Dermatol"},{"key":"348_CR68","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1053\/bega.2001.0236","volume":"15","author":"CJ Hawkey","year":"2001","unstructured":"Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001;15:801\u201320.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"348_CR69","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.2147\/DDDT.S84849","volume":"9","author":"E Campione","year":"2015","unstructured":"Campione E, Patern\u00f2 EJ, Candi E, Falconi M, Costanza G, Diluvio L, et al. The relevance of piroxicam for the prevention and treatment of nonmelanoma skin cancer and its precursors. Drug Des Devel Ther. 2015;9:5843\u201350.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"348_CR70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2165\/11311170-000000000-00000","volume":"11","author":"E Campione","year":"2010","unstructured":"Campione E, Diluvio L, Patern\u00f2 EJ, Chimenti S. Topical treatment of actinic keratoses with piroxicam 1% gel: a preliminary open-label study utilizing a new clinical score. Am J Clin Dermatol. 2010;11(1):45\u201350.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"348_CR71","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/03007995.2017.1313212","volume":"33","author":"M Puviani","year":"2017","unstructured":"Puviani M, Galloni C, Marchetti S. Efficacy of a film-forming medical device containing sunscreen (50\u00a0+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3\u00a0month trial. Curr Med Res Opin. 2017;33(7):1255\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"348_CR72","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000481770","volume":"9","author":"C Garofalo","year":"2017","unstructured":"Garofalo C, Ventura A, Mazzilli S. Treatment of multiple actinic keratosis and field of cancerization with topical piroxicam 0.8% and Sunscreen 50\u00a0+\u00a0in organ transplant recipients: a series of 10 cases. Case Rep Dermatol. 2017;9(3):211\u20136.","journal-title":"Case Rep Dermatol"},{"key":"348_CR73","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/archderm.139.10.1325","volume":"139","author":"M Urosevic","year":"2003","unstructured":"Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003;139:1325\u201332.","journal-title":"Arch Dermatol"},{"key":"348_CR74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/CCID.S121323","volume":"10","author":"R Khanna","year":"2017","unstructured":"Khanna R, Bakshi A, Amir Y, Goldenberg G. Patient satisfaction and reported outcomes on the management of actinic keratosis. Clin Cosmet Investig Dermatol. 2017;10:179\u201384.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"348_CR75","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.141.4.467","volume":"141","author":"N Korman","year":"2005","unstructured":"Korman N, Moy R, Ling M. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141:467\u201373.","journal-title":"Arch Dermatol"},{"key":"348_CR76","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000381420","volume":"231","author":"R Waalboer-Spuij","year":"2015","unstructured":"Waalboer-Spuij R, Holterhues C, van Hattem S, Schuttelaar MLA, Gaastra MTW, Kuijpers DIM, et al. Patient perception of imiquimod treatment for actinic keratosis and superficial basal cell carcinoma in 202 patients. Dermatology. 2015;231:56\u201362.","journal-title":"Dermatology"},{"key":"348_CR77","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2009.06.020","volume":"62","author":"CW Hanke","year":"2010","unstructured":"Hanke CW, Beer KR, Stockfleth E, Wu J, Rosen T, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. J Am Acad Dermatol. 2010;62:573\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"348_CR78","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jaad.2009.07.004","volume":"62","author":"N Swanson","year":"2010","unstructured":"Swanson N, Abramovits W, Berman B, Kulp J, Rigel DS, Levy S. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62:582\u201390.","journal-title":"J Am Acad Dermatol"},{"key":"348_CR79","first-page":"1278","volume":"12","author":"N Swanson","year":"2013","unstructured":"Swanson N, Smith CC, Kaur M, Goldenberg G. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 2013;12:1278\u201382.","journal-title":"J Drugs Dermatol"},{"key":"348_CR80","unstructured":"Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol 2008;7(1):23\u20135."},{"key":"348_CR81","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4103\/2229-5178.115538","volume":"4","author":"S Aditya","year":"2013","unstructured":"Aditya S, Gupta S. Ingenol mebutate: a novel topical drug for actinic keratosis. Indian Dermatol Online J. 2013;4:246\u20139.","journal-title":"Indian Dermatol Online J"},{"key":"348_CR82","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/bjd.14222","volume":"174","author":"C Garbe","year":"2016","unstructured":"Garbe C, Basset-Seguin N, Poulin Y, Larsson T, \u00d8sterdal ML, Venkata R, et al. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomized, controlled 12-month study. Br J Dermatol. 2016;174:505\u201313.","journal-title":"Br J Dermatol"},{"key":"348_CR83","first-page":"154","volume":"13","author":"B Berman","year":"2014","unstructured":"Berman B, Goldenberg G, Hanke CW, Tyring SK, Werschler WP, Knudsen KM, et al. Efficacy and safety of ingenol mebutate 0.015% gel 3\u00a0weeks after cryosurgery of actinic keratosis: 11-Week results. Journal of Drugs. Dermatology. 2014;13:154\u201360.","journal-title":"Dermatology"},{"key":"348_CR84","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jaad.2009.01.008","volume":"60","author":"L Anderson","year":"2009","unstructured":"Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025 and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60:934\u201343.","journal-title":"J Am Acad Dermatol"},{"key":"348_CR85","first-page":"AB193","volume":"72","author":"D Schaefer","year":"2015","unstructured":"Schaefer D. Survey of patient satisfaction with ingenol mebutate gel treatment of actinic keratosis from a community dermatology practice. J Am Acad Dermatol. 2015;72:AB193.","journal-title":"J Am Acad Dermatol"},{"key":"348_CR86","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1177\/0394632016648707","volume":"29","author":"S Nistic\u00f2","year":"2016","unstructured":"Nistic\u00f2 S, Torchia V, Gliozzi M, Bottoni U, Del Duca E, Muscoli C. Pharmacoeconomy of drugs used in the treatment of actinic keratoses. Int J Immunopathol Pharmacol. 2016;29:796\u2013804.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"348_CR87","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/jdv.14177","volume":"31","author":"E Sotiriou","year":"2017","unstructured":"Sotiriou E, Apalla Z, Vrani F, Lazaridou E, Vakirlis E, Lallas A, et al. Daylight photodynamic therapy vs. Conventional photodynamic therapy as skin cancer preventive treatment in patients with face and scalp cancerization: an intra-individual comparison study. J Eur Acad Dermatol Venereol. 2017;31:1303\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"16","key":"348_CR88","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJM199310143291602","volume":"329","author":"SC Thompson","year":"1993","unstructured":"Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329(16):1147\u201351.","journal-title":"N Engl J Med"},{"issue":"2","key":"348_CR89","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/archderm.1995.01690140054008","volume":"131","author":"MF Naylor","year":"1995","unstructured":"Naylor MF, Boyd A, Smith DW, Cameron GS. High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol. 1995;131(2):170\u20135.","journal-title":"Arch Dermatol"},{"issue":"Suppl 3","key":"348_CR90","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/j.1365-2133.2009.09453.x","volume":"161","author":"C Ulrich","year":"2009","unstructured":"Ulrich C, J\u00fcrgensen JS, Degen A. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24\u00a0months, prospective, case-control study. Br J Dermatol. 2009;161(Suppl 3):78\u201384.","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-018-0348-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-018-0348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T19:50:55Z","timestamp":1693597855000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-018-0348-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,26]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["348"],"URL":"https:\/\/doi.org\/10.1007\/s40257-018-0348-7","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,26]]},"assertion":[{"value":"26 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nathan Jetter, Neha Chandan, Stephanie Wang, and Maria Tsoukas have no potential conflicts of interest related to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}